The aromatase inhibitors (AIs) anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients. However, AIs are associated with significantly more osteoporotic fractures and greater bone mineral loss. As antiresorptive agents, oral and intravenous bisphosphonates such as alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), pamidronate (Aredia), and zoledronic acid (Zometa) have efficacy in preventing postmenopausal osteoporosis, cancer treatment-related bone loss, or skeletal complications of metastatic disease. Clinical practice guidelines recommend baseline and annual follow-up bone density monitoring for all patients initiating AI therapy. Bisphosphonate therapy should be prescribed for patients with osteoporosis (T score < -2.5) and considered on an individual basis for those with osteopenia (T score < -1). Modifiable lifestyle behaviors including adequate calcium and vitamin D intake, weight-bearing exercise, and smoking cessation should be addressed. Adverse events associated with bisphosphonates include gastrointestinal toxicity, renal toxicity, and osteonecrosis of the jaw. These safety concerns should be balanced with the potential of bisphosphonates to minimize or prevent the debilitating effects of AI-associated bone loss in patients with early, hormone receptor-positive breast cancer.
As a result of earlier diagnosis, more efficacious treatments, and longer survival, more patients than ever are receiving long-term treatment for breast cancer. Improved survival is due in part to the successful use of adjuvant hormonal therapies in estrogen and/or progesterone receptor-positive disease. The increasing breast cancer survivor population—estimated at slightly over 2 million women in the United States in 2005—may be at risk for long-term side effects of these beneficial treatments.
Recent randomized clinical trials have revealed the efficacy of aromatase inhibitors (AIs) as adjuvant therapy for early breast cancer in postmenopausal women.[3,4] However, the substantial benefits documented for this class of drug in the short term are associated with a significant, but manageable, increase in adverse events related to bone health. The cumulative incidence of AI-associated bone loss in patients with breast cancer in the long term is not known. The AIs anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) have been shown to be significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing disease recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients.[3-5] The growing use of AIs mandates vigilance about bone health in the oncology community. This article reviews the biology of AI-associated bone loss, summarizes recent safety data from clinical trials, and discusses options for preserving bone health in patients with breast cancer.
Pathophysiology of AI-Associated Bone Loss
The ongoing process of bone remodeling in the adult skeleton reflects a balance between the resorptive activity of osteoclasts and bone-forming action of osteoblasts, processes that are normally coupled and in equilibrium. Normal bone turnover is maintained through a complex regulatory system of both systemic and local factors. Molecular factors involved in bone resorption and remodeling include osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and RANK ligand (RANKL). RANKL activates and binds to the RANK receptor on osteoclasts and their precursor cells, promoting osteoclast formation and prolonged osteoclast lifespan. Osteoprotegerin acts as a decoy receptor of RANKL and inhibits RANKL binding to RANK. Altering the relative biological availabilities of OPG and RANKL has direct consequences for the regulation of normal bone remodeling and in the pathogenesis of cancer-induced bone loss.[7,8]
Estrogen and Bone Physiology
Although the importance of the steroid sex hormones in bone metabolism has been recognized for many decades, their cellular and molecular mechanisms of action are still being elucidated.[3,9] Broadly speaking, estrogen has suppressive, antiresorptive effects on osteoclasts during bone remodeling. These pleiotropic effects are mediated through intracellular and cell surface estrogen receptors expressed by osteoclasts and osteoblasts and are largely indirect. For example, estrogen modulates osteoblast-derived cytokines, resulting in decreased differentiation and maturation of osteoclasts from precursors and increased osteoclast apoptosis (programmed cell death).[6,9] Estrogen may also induce direct effects on osteoblasts, further favoring bone formation over resorption. In concert, these cellular responses have the net effect of dampening bone turnover under estrogen-replete conditions (Figure 1).
Estrogen deprivation that occurs with natural or treatment-associated menopause increases bone turnover and osteoclast activity, causing bone resorption and formation to become unbalanced. This imbalance results in net bone loss as well as decreased bone quality, a term that encompasses both bone microarchitecture and degree of mineralization. Bone quality is increasingly recognized as an important determinant of overall bone health, and studies have shown that substantial deterioration of bone microarchitecture can occur before bone density is affected.
Estrogen Blockade With AIs
In the postmenopausal state, the bulk of estrogen production switches from the ovaries to other sites such as adipose tissue, adrenal glands, smooth muscle, and bone.[3,9] Adrenally derived androgens circulate to peripheral tissues where they are converted to estrogen by the action of the enzyme aromatase (also called estrogen synthetase). This residual postmenopausal estrogen, although substantially reduced, remains critical for bone health.
The mechanism of action of the AIs is to block the peripheral conversion (aromatization) of estrogen from androgen precursors, effectively lowering tissue and circulating estrogen levels.[1,3] The AIs currently approved for adjuvant use in receptor-positive breast cancer in the United States belong to two distinct biochemical classes (Figure 2). The steroidal AI exemestane is a derivative of androstenedione that irreversibly occupies the aromatase substrate-binding site and may be considered an aromatase inactivator. Exemestane is approved as second-line treatment, after 2 to 3 years of tamoxifen, for early hormone receptor-positive breast cancer.
Nonsteroidal inhibitors such as anastrozole and letrozole bind reversibly to the cytochrome P450 domain of aromatase. Anastrazole is approved as first-line adjuvant treatment of hormone receptor-positive early breast cancer. Letrozole is currently approved as second-line treatment, within 3 months of completion of 5 years of tamoxifen, for early hormone receptor-positive breast cancer. Because they do not inhibit estrogen synthesis in functioning ovaries, AIs are not indicated for use in premenopausal or perimenopausal patients with breast cancer. All of these third-generation AIs inhibit aromatase activity by more than 98% and are more potent than earlier drug entities.[1,3]
Unique Aspects of AI-Associated Bone Loss
Treatment-associated bone loss after cancer therapies such as oophorectomy, cytotoxic chemotherapies (eg, doxorubicin and cyclophosphamide), and endocrine therapies may be distinct from normal postmenopausal bone loss. Estrogen deprivation that occurs after ovarian ablation or during AI therapy is generally abrupt compared with that occurring postmenopausally. In addition, treatment-related bone loss may occur at an accelerated rate. The rate of bone loss is estimated at 2% annually during the first years after the onset of menopause, leveling out to ~1% during the next decade and thereafter. In contrast, compared with untreated postmenopausal women, patients with breast cancer who receive AIs experience a rate of bone loss estimated at 2.6% per year. Premenopausal women who receive AIs in combination with a gonadotropin-releasing hormone (GnRH) agonist to effect complete ovarian suppression, or with ovarian failure secondary to chemotherapy, have even higher rates of bone loss—approximately 7% annually.[14,15]
Low bone mineral density (BMD) is a critical factor associated with pathologic fracture. The risk to patients inherent in bone loss is underscored by the exponential increase in vertebral and hip fracture with decreasing BMD, expressed as the T score (Figure 3 and Table 1). Decreases in bone density of 10% to 15% have been shown to approximately double the risk of fracture, and even modest BMD increases can offer substantial preventative benefit. Cumulative increases in BMD of at least 5% have been achieved with bisphosphonates in postmenopausal osteoporosis. Increased BMD with bisphosphonates may result from the remineralization of established bone formation units, rather than from an increase in new bone.
Bone Turnover Markers and AIs
Bone turnover markers are biochemical products of osteoblasts and osteoclasts that reflect bone turnover in the whole skeleton (Table 2).[18,19] Clinically useful osteoblast-derived formation markers include the bone-specific isoform of the enzyme alkaline phosphatase (BALP), the C- and N-terminal propeptides of type 1 collagen (PICP, PINP), and osteocalcin (OC). Markers of osteoclast-mediated bone resorption include the collagen breakdown products, C- and N-telopeptide cross-links (CTX, NTX), pyridinoline (PYD), deoxypyridinoline (DPD), and tartrate-resistant acid phosphatase (TRACP). Assays for the measurement of bone formation markers (BALP and OC) and bone resorption markers (NTX, PYD, and DPD) are commercially available and approved by the US Food and Drug Administration.
Increases in bone turnover markers approaching 100% may result from decreased estrogen levels at menopause. Similarly, postmenopausal patients with breast cancer who are treated with AIs have significantly higher levels of the urinary bone resorption markers PYD and DPD. Data from the placebo arms of two large randomized trials on the treatment of bone metastases secondary to prostate, non-small-cell lung cancer and other solid tumors with zoledronic acid found baseline levels of both NTX and BALP were highly predictive of subsequent skeletal complications.
Suppression of bone resorption and formation markers has been correlated with clinical outcomes and with clinical response to antiresorptive therapy. A recent study in 328 breast cancer patients with bone metastases found zoledronic acid therapy for 3 months resulted in normalization of bone marker levels in 76% of patients with elevated levels at baseline. Patients with normalized markers had significantly improved survival compared to patients whose bone marker levels were not normalized. Although these recent data suggest that bone marker data may someday be useful in predicting clinical outcome for patients at risk for skeletal events, bone marker monitoring is not yet considered reliable for screening or diagnostic purposes.[24,25]
1. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005.
2. American Cancer Society: Breast Cancer Facts & Figures 2005-2006. Available at www.cancer.org. Accessed July 12, 2006.
3. Osborne C, Tripathy D: Aromatase inhibitors: Rationale and use in breast cancer. Ann Rev Med 56:103-116, 2005.
4. Mincey BA, Perez EA: Aromatase inhibitors and bone health, in ASCO 2005 Education Book, pp 27-34. 41st Annual Meeting, Orlando, Florida, 2005.
5. Goss PE, Strasser-Weippl K: Prevention strategies with aromatase inhibitors. Clin Cancer Res 10(suppl):372s-379s, 2004.
6. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495, 2004.
7. Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts and prospects. J Clin Invest 115:3318-3325, 2005.
8. Blair JM, Zhou H, Seibel MJ, et al: Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Prac Clin Oncol 3(1):41-49, 2006.
9. Riggs BL, Khosla S, Melton LJ, III: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302, 2002.
10. Benito M, Gomberg B, Wehrli FW, et al: Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 88:1497-1502, 2003.
11. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18:1570-1593, 2000.
12. Kanis JA: Pathogenesis of osteoporosis and fracture, in Kanis JA (ed): Osteoporosis, pp 22-55. London, Blackwell Healthcare Communications, 1997.
13. Eastell R, Hannon RA, Cuzick J, et al: Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) Study (abstract 1170). J Bone Miner Res 17(suppl 1):S165, 2002.
14. Gnant M, Jakesz R, Mlineritsch B, et al: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen-Bone density subprotocol results of a randomized multicenter trial (ABCSG-12) (abstract 6). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 8, 2004.
15. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306-3311, 2001.
16. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: Scientific review. JAMA 288:1889-1897, 2002.
17. Actonel (risedronate sodium tablets) prescribing information. Cincinnati, Procter & Gamble, 2005.
18. Garnero P, Sornay-Rendu E, Chapuy MC, et al: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349, 1996.
19. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Clin Orthop Relat Res Oct(415 suppl):S138-S147, 2003.
20. Heshmati HM, Khosla S, Robins SP, et al: Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17:172-178, 2002.
21. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005.
22. Lipton A, Hei YJ, Coleman RE, et al: Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer (abstract 3015). Presented at the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005.
23. Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12-month BMD results of the Z-FAST trial (abstract 533). Proc Am Soc Clin Oncol 23:12S, 2005.
24. Hillner BE, Ingle JN, Chlebowski RT: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
25. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC, National Osteoporosis Foundation, 2003. Available at http://www.nof.org
26. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003.
27. Howell A, Cuzick J, Baum M, et al, for the ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
28. Coleman RE, on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex,' Tamoxifen, Alone or in Combination (ATAC) trial (abstract 511). J Clin Oncol 24(suppl 18S):5s, 2006.
29. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003.
30. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005.
31. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 24(22):3629-3635, 2006.
32. Thurlimann BJ, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 Collaborative Group. N Engl J Med 353:2747-2757, 2005.
33. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005.
34. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
35. Coleman RE, Banks LM, Hall E, et al, for the Intergroup Exemestane Study: Intergroup Exemestane Study: 1 year results of the bone sub-protocol (abstract 401). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 10, 2004.
36. Lonning PE, Geisler J, Krag LE, et al: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137, 2005.
37. Lonning PE, Geisler J, Krag LE, et al: Changes in bone metabolism after 2 years' treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study (abstract 531). Proc Am Soc Clin Oncol 23:11s, 2005.
38. Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65-74, 2003.
39. Green JR, Müller K, Jaeggi KA: Preclinical pharmacology of CGP 42 ¢446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 745-751, 1994.
40. Saarto T, Blomqvist C, Välimäki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997.
41. Vehmanen L, Saarto T, Risteli J, et al: Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188, 2004.
42. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997.
43. Ripps BA, VanGilder K, Minhas B, et al: Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. J Reprod Med 48:761-766, 2003.
44. Smith MR, McGovern FJ, Zietman AL, et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 345:948-955, 2001.
45. Mincey BA, personal communication.
46. Fosamax (alendronate sodium) tablets prescribing information. Whitehouse Station, NJ, Merck, 2005.
47. Boniva (ibandronate sodium) tablets complete product information. Nutley, NJ, Roche, 2005.
48. Zometa (zoledronic acid) injection prescribing information. East Hanover, NJ, Novartis, 2005.
49. Pamidronate (disodium) for injection prescribing information. Bedford, Ohio, Bedford Laboratories, 2001.
50. Caro JJ, Ishak KJ, Huybrechts KF, et al: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int [serial online] May 27, 2004.
51. Ruggiero SL, Gralow J, Marx RE, et al: Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14, 2006.
52. Durie BGM, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102, 2005.
53. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587, 2005.
54. Bekker, PJ, Holloway DL, Rasmussen AS, et al: A single dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066, 2004.
55. Available at www.clinicaltrials.gov. Accessed July 12, 2006.
56. Lipton A, Alvarado C, DeBoer R, et al: Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with IV bisphosphonates (abstract 512). J Clin Oncol 24(suppl 18S):6s, 2006.
57. Mincey BA, Duh MS, Thomas SK, et al: Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7(2):127-132, 2006.
58. National Comprehensive Cancer Network: Clinical practice guidelines in oncology. Breast cancer v.2.2005. Available at www.nccn.org. Accessed July 12, 2006.
59. Nieves J: Nutrition, in Cummings SR, Cosman F, Jamal SA (eds): Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp 85-108. Philadelphia, American College of Physicians, 2002.
60. Holick MF: Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362-371, 2004.
61. Zinaman RS, Van Poznak CH, Goldberg LM, et al: Supplemental calcium and vitamin D intake of women with early stage breast cancer (abstract 4006). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December 10, 2004.
62. Rubin C, Recker R, Cullen D, et al: Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: A clinical trial assessing compliance, efficacy, and safety. J Bone Miner Res 19:343-351, 2004.
63. Chen Z, Maricic M, Bassford TL, et al: Fracture risk among breast cancer survivors results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558, 2005.